For punkt 4. 4 indførte CHMP en revideret formulering for afsnittet om hyperprolaktinæmi, hvor specifik omtale af prolaktinom og brystcancer udelukkes, da data trods dataunderstøttelse for en mulig sammenhæng mellem hyperprolaktinæmi og risiko for visse prolaktinafhængige tumorer stadig i vidt omfang ikke er sikre ud fra et klinisk perspektiv.
For section 4.4, the CHMP implemented a revised wording for the hyperprolactinaemia section, excluding specific mention of prolactinoma and breast cancer, as although data supporting a possible relationship between hyperprolactinaemia and risk of some prolactin-dependent tumours exists, the data is still largely inconclusive from a clinical perspective.